Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethinyl estradiol + cyproterone is a fixed-dose combination oral medication containing two active ingredients: ethinyl estradiol, a synthetic estrogen, and cyproterone acetate, a synthetic progestogen with anti-androgenic properties. This combination is primarily used to treat women of reproductive age with moderate to severe acne related to androgen sensitivity or hirsutism (excessive hair growth), especially when other treatments have failed. Cyproterone acetate acts as an androgen receptor antagonist and suppresses ovarian androgen production, while ethinyl estradiol provides estrogenic activity that helps regulate the menstrual cycle and further reduces circulating androgens by increasing sex hormone-binding globulin. The combination also has contraceptive effects but should not be used solely for birth control due to an increased risk of thromboembolism compared to some other oral contraceptives[1][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + cyproterone.